Skip to content

Deferred Taxes at other companies

Viatris logo
ViatrisVTRS
-$69.7M-59.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$0+100%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$9.28M
Amgen logo
AmgenAMGN
-$176M+29.6%
Organon logo
OrganonOGN
$3M+118%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.34M+0.6%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxesAndTaxCredits.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's deferred taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's deferred taxes?
ANI Pharmaceuticals (ANIP) reported deferred taxes of $2.52M in Q1 2026.
How has ANI Pharmaceuticals's deferred taxes changed year-over-year?
ANI Pharmaceuticals's deferred taxes increased by 174.3% year-over-year, from -$3.38M to $2.52M.
What is the long-term trend for ANI Pharmaceuticals's deferred taxes?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's deferred taxes has grown at a -4.0% compound annual growth rate (CAGR), from -$16.75M to $14.24M.
What does deferred taxes mean?
Non-cash deferred tax expense or benefit representing the change in deferred tax assets/liabilities during the period.